Literature DB >> 19560994

Hepatitis C virus infection and metabolic syndrome---a community-based study in an endemic area of Taiwan.

Jee-Fu Huang1, Wan-Long Chuang, Ming-Lung Yu, Sung-Hua Yu, Chung-Feng Huang, Ching-I Huang, Ming-Lun Yeh, Meng-Hsuan Hsieh, Jeng-Fu Yang, Zu-Yau Lin, Shinn-Chern Chen, Chia-Yen Dai, Wen-Yu Chang.   

Abstract

Metabolic syndrome (MS) is a complicated disorder associated with a high risk of future development of micro- and macrovascular complications. The extrahepatic manifestations of hepatitis C virus (HCV) infection can include multiple metabolic abnormalities. However, the extent, severity, and characteristics of MS in HCV-infected patients have rarely been investigated in community-based settings. This study aimed to determine the difference in prevalence and distribution of the components of MS between HCV-infected patients and healthy controls. Multipurpose mass screening of adults was conducted in an HCV-endemic area of Southern Taiwan. Clinical profiles in terms of anthropometric data and MS components, as well as viral hepatitis markers, were assessed. Two hundred and thirty-seven adults (94 males; mean age, 55.5 +/- 10.8 years) were recruited. The prevalence of anti-HCV seropositivity was 39.2% (93/237). The prevalence of MS was higher in the HCV-infected individuals (24.7%, 23/93) than in the control, uninfected subjects (13.2%, 19/144, p = 0.02). In terms of MS components, HCV-infected subjects had a higher prevalence of high waist circumference (51.6% vs. 25.7%, p < 0.001) and hypertension (58.1% vs. 36.8%, p = 0.001) than controls. Multivariate logistic regression analysis demonstrated that anti-HCV positivity was significantly associated with MS (odds ratio, 6.4; 95% confidence interval, 1.82-22.84; p = 0.004). HCV infection was associated with a higher prevalence of MS. Determination of MS in patients with HCV infection could therefore be indicated.

Entities:  

Mesh:

Year:  2009        PMID: 19560994     DOI: 10.1016/S1607-551X(09)70520-0

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  12 in total

Review 1.  A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan.

Authors:  Heather Bennett; Nathalie Waser; Karissa Johnston; Jia-Horng Kao; Young-Suk Lim; Zhong-Ping Duan; Youn-Jae Lee; Lai Wei; Chien-Jen Chen; William Sievert; Yong Yuan; Hong Li
Journal:  Hepatol Int       Date:  2015-06-13       Impact factor: 6.047

2.  Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C.

Authors:  Jee-Fu Huang; Chao-Kuan Huang; Ming-Lung Yu; Chia-Yen Dai; Chung-Feng Huang; Wei-Wen Hung; Ming-Lun Yeh; Meng-Hsuan Hsieh; Jeng-Fu Yang; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Chern Chen; Shun-Sheng Wu; Wan-Long Chuang
Journal:  Hepatol Int       Date:  2011-08-18       Impact factor: 6.047

3.  Serum hs-CRP was correlated with treatment response to pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.

Authors:  Chung-Feng Huang; Ming-Yen Hsieh; Jeng-Fu Yang; Wu-Cheng Chen; Ming-Lun Yeh; Ching-I Huang; Chia-Yen Dai; Ming-Lung Yu; Zu-Yau Lin; Shinn-Chern Chen; Wan-Long Chuang; Jee-Fu Huang
Journal:  Hepatol Int       Date:  2010-08-04       Impact factor: 6.047

4.  Thyroid dysfunction in Chinese hepatitis C patients: Prevalence and correlation with TPOAb and CXCL10.

Authors:  Ren-Wen Zhang; Cui-Ping Shao; Na Huo; Min-Ran Li; Hong-Li Xi; Min Yu; Xiao-Yuan Xu
Journal:  World J Gastroenterol       Date:  2015-09-07       Impact factor: 5.742

Review 5.  Metabolic alterations and hepatitis C: From bench to bedside.

Authors:  Ming-Ling Chang
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

6.  Metabolic syndrome in patients with chronic hepatitis C virus genotype 1 infection who do not have obesity or type 2 diabetes.

Authors:  Lucivalda Pereira Magalhães Oliveira; Rosangela P de Jesus; Ramona S S B Boulhosa; Carlos Mauricio C Mendes; Andre Castro Lyra; Luiz Guilherme C Lyra
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

7.  Increased prevalence of coronary artery disease risk markers in patients with chronic hepatitis C--a cross-sectional study.

Authors:  Torsten Roed; Ulrik Sloth Kristoffersen; Andreas Knudsen; Niels Wiinberg; Anne-Mette Lebech; Thomas Almdal; Reimar W Thomsen; Andreas Kjær; Nina Weis
Journal:  Vasc Health Risk Manag       Date:  2014-01-21

Review 8.  Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review.

Authors:  Anne-Claire Desbois; Patrice Cacoub
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742

Review 9.  Host factors determining the efficacy of hepatitis C treatment.

Authors:  Wan-Long Chuang; Ming-Lung Yu
Journal:  J Gastroenterol       Date:  2012-10-27       Impact factor: 7.527

10.  Association between hepatitis B virus infection and metabolic syndrome: a retrospective cohort study in Shanghai, China.

Authors:  Yanbing Zhou; Yan Cui; Haiju Deng; Jinming Yu
Journal:  BMC Public Health       Date:  2014-05-28       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.